Skip to main content

Table 1 General characteristics of the study cohort at inclusion

From: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial

Variable Control group Prone group
Count 39 36
Male 32 (82%) 23 (64%)
Age 65 [55–70] 66 [53–74]
BMI 29 [27–33] 28 [25–30]
Obesity (BMI ≥ 30 kg m−2) 12 (32%) 8 (23%)
Hypertension 21 (55%) 17 (47%)
Ischemic cardiac disease 5 (13%) 6 (17%)
Congestive heart failure 6 (15%) 2 (6%)
Lung disease 10 (26%) 4 (11%)
Asthma 5 (13%) 1 (3%)
COPD 4 (10%) 2 (6%)
Fibrosis 0 (0%) 1 (3%)
Sarcoidosis 1 (3%) 0 (0%)
Diabetes mellitus 11 (28%) 14 (39%)
Renal diseasea 2 (5%) 3 (8%)
Active cancer 1 (3%) 4 (11%)
Liver disease 1 (3%) 0 (0%)
Enrollment outside ICU 20 (51%) 19 (53%)
HFNO 29 (74%) 31 (86%)
Flow rate (HFNO) 50 [40–50] 50 [40–50]
PEEP (NIV) 8 [6–8] 7 [6–10]
FiO2 0.6 [0.55–0.70] 0.6 [0.55–0.70]
SpO2 94 [92–95] 93 [91–94]
PaO2 9.2 [8.2–10] 8.8 [7.7–9.7]
RR 26 [23–32] 24 [21–29]
PaO2/FiO2 ratio 15.4 [12.5–17.3] 15.4 [11.5–17.4]
SpO2/FiO2 ratio 157 [136–175] 151 [131–174]
SBP 130 [120–140] 130 [120–140]
DBP 70 [60–80] 69 [62–75]
  1. Categorical parameters are presented as n (%), continuous variables as median (interquartile range [IQR]); COPD, Chronic obstructive pulmonary disease; BMI, Body Mass Index; ICU, Intensive Care Unit; HFNO High-flow Nasal Oxygen; PEEP, Positive End Expiratory Pressure; NIV Noninvasive ventilation; RR, Respiratory Rate; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure
  2. aCreatinine clearance < 60 mL min−1